GHK-Cu's published endpoints fall on four very different clocks. Gene-expression signatures appear within hours of adding the compound to a culture dish. Hair-follicle organ-culture elongation is tracked over roughly a week to ten days in culture. Rodent and pig wound-closure endpoints run one to several weeks. Human topical skin studies run the longest, with clinical and biopsy endpoints typically assessed across a multi-week application period. There is no single "week 4" number that applies to all four; each model has its own timeline, reported below with its study.
That spread matters for reading any claim about GHK-Cu "results." A gene-expression finding from hour one in a dish and a skin-biopsy finding from week twelve of topical use are both real data, but they answer completely different questions. The tables below separate what was measured, in which model, at which point in the study.
| Key fact | Value reported | Source |
|---|---|---|
| Fastest reported endpoint | Genome-wide expression signature, captured within hours of culture exposure | Lamb et al., 2006 |
| Shortest tissue-level endpoint | Hair shaft elongation in follicle organ culture, measured over roughly a week to ten days | Pyo et al., 2007 |
| Animal wound-closure endpoints | Tracked across the wound-closure period in rat and pig open-wound models, typically one to several weeks | Canapp et al., 2003; related rodent wound literature |
| Longest human endpoint window located | Clinical and biopsy grading across a multi-week topical application period in a photodamaged-skin trial | Abdulghani et al. |
| Endpoint most specific to GHK-Cu's mechanism | Collagen synthesis in fibroblast culture, measured directly, not as a weekly series | Maquart et al., 1988 |
What is the fastest endpoint reported for GHK-Cu?
Gene expression. Lamb et al. (2006) added GHK directly to cultured human cell lines as part of the Broad Institute's Connectivity Map and profiled genome-wide expression within hours of exposure, not days or weeks. That signature, a defined pattern of genes turned up or down relative to vehicle, is the fastest reported readout in the GHK-Cu literature and the one most often cited when the compound is described as a broad modulator of cellular gene expression. It is a single-timepoint, in vitro measurement; the Connectivity Map approach was not designed to track a signature across multiple weeks the way a skin or wound study is. For the mechanism behind that signature, see ghk-cu-copper-binding-and-collagen-research.
What does the hair-follicle literature measure, and over what period?
Pyo et al. (2007) cultured isolated human scalp hair follicles ex vivo and measured hair shaft elongation with GHK-Cu added to the culture medium, tracking elongation over the course of the organ-culture period, which in this kind of follicle assay typically runs under two weeks before the follicle degrades in culture. The finding was an increase in shaft elongation relative to follicles kept in control medium. This is an isolated-organ, laboratory endpoint; it says nothing about a living scalp, a multi-week human study, or any endpoint beyond the culture window itself.
What does the wound-model literature show week by week?
The clearest week-resolved animal data come from the ischemic open-wound pig model in Canapp et al. (2003), where a topical tripeptide-copper complex was applied repeatedly to the wound bed and wound-closure parameters were tracked against control wounds across the study period, with the comparison reported at the end of that closure window. Related rat full-thickness wound work from the same research lineage applied the complex topically and measured new collagen deposition in the wound bed in the early weeks after wounding, when collagen deposition is most active, finding higher deposition than in untreated or vehicle-treated wounds. Neither paper reports a uniform week 4, 8 and 12 series; each reports its endpoint at the time point built into that specific wound-closure model.
What does the human skin literature measure, and for how long?
The longest tracked window in the GHK-Cu literature belongs to human topical skin trials. Abdulghani et al. compared a topical copper-binding peptide cream against other topical actives on photodamaged facial skin, applying the test creams across a multi-week period and assessing clinical grading and skin-biopsy collagen content at intervals through that period, with the key comparison reported at the end of the study. This is the only located human controlled trial with a reported multi-week assessment structure for GHK-Cu; it is also narrower in scope than the animal wound data, since its endpoints are limited to visible skin and biopsy-level collagen rather than full-thickness wound closure.
Why doesn't the gene-expression finding show up on the same timeline as the skin studies?
Because it is a different kind of measurement entirely. The Connectivity Map signature is a snapshot: cultured cells exposed to GHK at a set concentration, profiled once, within hours. The skin and wound studies are repeated-measures designs: the same wound or the same skin area assessed more than once as weeks pass. Citing the gene-expression finding as if it were a "week 4" or "week 12" result conflates an acute in vitro readout with a tracked clinical or histological endpoint, and the two should not be merged into one timeline.
Timeline: what was measured, and when
| Timepoint | Study | What was measured | Finding reported |
|---|---|---|---|
| Within hours of exposure | Lamb et al., 2006 | Genome-wide gene-expression signature in cultured human cell lines | Distinct expression signature versus vehicle, entered into the Connectivity Map reference library |
| Direct measurement, not time-series | Maquart et al., 1988 | Collagen synthesis in fibroblast culture | Stimulated collagen synthesis versus untreated culture |
| Under two weeks (organ-culture period) | Pyo et al., 2007 | Hair shaft elongation in follicle organ culture | Increased elongation versus control medium |
| Early weeks after wounding | Rat full-thickness wound literature | New collagen deposition in the wound bed | Higher collagen deposition than untreated or vehicle-treated wounds |
| Across the wound-closure period (pig model) | Canapp et al., 2003 | Wound-closure parameters, histology | Favorable closure parameters versus control wounds by study end |
| Across a multi-week topical application period (human) | Abdulghani et al. | Clinical skin grading, biopsy collagen content | Measurable improvement versus comparator and placebo arms by the end of the study |
| Week 8 to week 12, human, compound-specific | No study located reports this exact interval for GHK-Cu | Not established | Data gap |
Study table
| Study | Model and n | Amount and route, as reported | Endpoint | Finding |
|---|---|---|---|---|
| Maquart et al., 1988 (PubMed 2460283) | Human skin fibroblast cultures | GHK-Cu complex added to culture medium at micromolar concentrations, in vitro | Collagen synthesis (labeled proline incorporation) | Stimulated collagen synthesis versus untreated culture |
| Simeon et al., 2000 (PubMed 11057670) | Human skin fibroblast cultures | GHK-Cu complex added to culture medium, in vitro | Matrix metalloproteinase-2 expression | Increased MMP-2 expression, consistent with extracellular matrix remodeling |
| Pyo et al., 2007 (PubMed 17703054) | Human scalp hair follicles, organ culture (ex vivo) | GHK-Cu added directly to follicle culture medium at defined concentrations | Hair shaft elongation in culture | Increased follicle elongation versus control medium |
| Canapp et al., 2003 (PubMed 14669421) | Pig model, ischemic open wounds | Topical tripeptide-copper complex applied to the wound surface, repeated application across the study period | Wound-closure rate, histology | Favorable closure parameters versus control wounds |
| Abdulghani et al. | Human adults with photodamaged facial skin, placebo- and comparator-controlled | Topical copper-binding peptide cream applied to facial skin across a multi-week period | Clinical skin grading, biopsy collagen | Measurable improvement in photodamage parameters versus comparator and placebo arms |
| Lamb et al., 2006 (PubMed 17008526) | Multiple cultured human cell lines | GHK added to culture medium across a concentration range, in vitro, for gene-expression profiling | Genome-wide expression signature | GHK produced a distinct expression signature entered into the Connectivity Map reference library |
| Pickart and Thaler, 1973 (PubMed 4706941) | Human plasma fraction tested on cultured normal and neoplastic rat liver cells | Tripeptide fraction isolated from plasma, added directly to culture medium at defined concentrations, in vitro | Cell survival and growth in culture | Fraction prolonged survival of normal liver cells and stimulated growth of neoplastic liver cells in culture |
How this is handled in a research setting
The copper-binding-peptide-ghk-cu vial and the blended glow-mix format both ship as lyophilized powder and are reconstituted immediately before any culture or bench work; the concentration math for turning a milligram amount into a working solution is covered in reconstituting-lyophilized-peptides. Because the active complex includes a bound copper ion, a quick look at solution color and clarity is a useful bench check alongside the paperwork; what the certificate of analysis should state about identity and purity is explained in how-to-read-a-peptide-coa. Every endpoint above came from a defined concentration and a defined exposure window; matching those two variables is what makes a bench result comparable to the published literature at all.
Frequently asked questions
Is there a published GHK-Cu study that tracks the same endpoint at week 4, week 8 and week 12?
Not one located for this article. The closest human data, from Abdulghani et al., report endpoints across a multi-week topical application period with a reported comparison at the end of the study rather than a uniform three-point series at those exact weeks.
How long are hair-follicle organ-culture studies usually run?
The specific GHK-Cu follicle study used an organ-culture window of roughly a week to ten days, consistent with how long an isolated human hair follicle typically remains viable ex vivo before culture-based assays like this one end.
Does the gene-expression signature change if GHK is left in culture for weeks instead of hours?
Not reported in Lamb et al. (2006), which profiled expression at a single, early timepoint after exposure. A longer-exposure time-course for the gene-expression signature specifically was not located in the published literature.
What is the earliest wound-model timepoint where a GHK-Cu effect has been reported?
Early-wound collagen deposition work in rat models has reported differences in the first one to two weeks after wounding, which is when collagen deposition is most active in a closing wound bed.
Is the skin-biopsy collagen endpoint the same kind of measurement as the fibroblast-culture collagen endpoint?
No. Maquart et al. (1988) measured collagen synthesis directly in a fibroblast culture dish using labeled proline incorporation. The Abdulghani human trial measured collagen content in a skin biopsy taken from a person after weeks of topical use. Both point to collagen, but one is a cell-culture assay and the other is tissue taken from skin that received the topical formulation.
How does this endpoint timeline compare to the GLOW and KLOW blend formats?
GHK-Cu's own endpoint literature, summarized above, is the basis for including it in blended formats; how it is combined with other tissue-focused peptides in those blends, and why KPV is added in one version, is covered in glow-vs-klow-blends-explained.
Where can I read more about GHK-Cu's basic mechanism before comparing endpoints?
Start with what-is-ghk-cu for the structure and copper-binding chemistry, then ghk-cu-copper-binding-and-collagen-research for how that chemistry connects to the collagen and gene-expression findings summarized here.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature. 1973;243(5405):85-87. PubMed 4706941.
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PubMed 2460283.
- Simeon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-2265. PubMed 11057670.
- Canapp SO Jr, Farese JP, Schultz GS, Gowda S, Ishak AM, Swaim SF, Vangilder J, Lee-Ambrose L, Martin FG. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-523. PubMed 14669421.
- Abdulghani AA, Sherr A, Shirin S, et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and alpha-tocopherol on cutaneous photodamage: a placebo-controlled, double-blind study. Dis Mon. 1998;44(1):1009-1013.
- Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. PubMed 17703054.
- Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-1935. PubMed 17008526.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



